BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19638468)

  • 1. Persuading natural killer cells to eliminate bad B cells.
    Cooper LJ
    Clin Cancer Res; 2009 Aug; 15(15):4790-1. PubMed ID: 19638468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.
    Altvater B; Landmeier S; Pscherer S; Temme J; Schweer K; Kailayangiri S; Campana D; Juergens H; Pule M; Rossig C
    Clin Cancer Res; 2009 Aug; 15(15):4857-66. PubMed ID: 19638467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.
    De Oliveira SN; Ryan C; Giannoni F; Hardee CL; Tremcinska I; Katebian B; Wherley J; Sahaghian A; Tu A; Grogan T; Elashoff D; Cooper LJ; Hollis RP; Kohn DB
    Hum Gene Ther; 2013 Oct; 24(10):824-39. PubMed ID: 23978226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
    Marin V; Kakuda H; Dander E; Imai C; Campana D; Biondi A; D'Amico G
    Exp Hematol; 2007 Sep; 35(9):1388-97. PubMed ID: 17656004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
    Davila ML; Bouhassira DC; Park JH; Curran KJ; Smith EL; Pegram HJ; Brentjens R
    Int J Hematol; 2014 Apr; 99(4):361-71. PubMed ID: 24311149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.
    Choi Y; Yuen C; Maiti SN; Olivares S; Gibbons H; Huls H; Raphael R; Killian TC; Stark DJ; Lee DA; Torikai H; Monticello D; Kelly SS; Kebriaei P; Champlin RE; Biswal SL; Cooper LJ
    Biomed Microdevices; 2010 Oct; 12(5):855-63. PubMed ID: 20574820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR therapy: the CD19 paradigm.
    Sadelain M
    J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
    Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
    Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.